福元医药(601089.SH)参与国家组织集采药品协议期满品种接续采购拟中选

Core Viewpoint - The company, Fuyuan Pharmaceutical (601089.SH), participated in the national organized procurement for drugs whose agreements are expiring, with selected products expected to positively impact future business performance despite a decrease in sales prices [1] Group 1: Procurement Participation - The company announced its participation in the national organized procurement for drugs with expiring agreements on February 9, 2026 [1] - The results of the procurement are expected to be implemented by the end of March 2026, with provincial medical institutions signing contracts based on the selected results [1] Group 2: Selected Products and Market Impact - The company has several products, including Ezetimibe tablets, proposed for selection in this procurement [1] - Although the sales prices of selected drugs are expected to decrease, the company aims to stabilize its existing market share and potentially increase market penetration due to its brand influence and reliable supply capabilities [1]